nivolumab
bms
['hncsm', 'nivo']
proud to have prof mirghani present our immune boost hpv trial at #esmo22 after 2 cycles of neoadjuvant nivo, 90% hpv+ high risk localized oropharyngeal cancer pts could receive full dose chemoradiation. pfs preliminary but encouraging compared to control pts. #hncsm #radonc 
Full Prof Radiation Oncology @gustaveroussy @UnivParisSaclay. EiC https://t.co/ZZv4fFrcCi. Director @SciencesCancer. Adjunct Assoc Prof @MDAndersonNews.